Enterprise Therapeutics’ TMEM16A potentiator program acquired by Roche

Enterprise Therapeutics, a drug discovery company developing novel therapies for the treatment of respiratory diseases, announced its TMEM16A potentiator portfolio has been fully acquired by Roche and will be developed by Genentech, a member of the Roche Group. The portfolio includes ETD002, a first-in-class inhaled cystic fibrosis (CF) therapy, which is currently in Phase 1.

TMEM16A (ANO1, anoctamin-1) is a calcium-activated chloride channel expressed in airway secretory epithelia. TMEM16A potentiation is regarded as a promising novel approach for the treatment of patients with CF and also non-CF lung diseases.

In preclinical models, ETD002 enhanced the activity of TMEM16A, increased epithelial fluid secretion and enhanced mucus clearance.

Read the press release here.

Read more about Enterprise Therapeutics here.

Photo by CDC on Unsplash